Glucocorticoids are sometimes used as “bridging” therapy to alleviate symptoms in newly diagnosed patients with rheumatoid arthritis until a disease-modifying antirheumatic drug (DMARD) kicks in. Test your knowledge of bridging therapy with this quiz.
In 2021 the American College of Rheumatology conditionally recommended that a conventional synthetic DMARD is initiated without short-term (<3 months) glucocorticoids. Its previous 2015 guideline for the Treatment of Rheumatoid Arthritis had recommended use of glucocorticoids as bridging therapy in patients with early rheumatoid arthritis with moderate to high disease activity until the benefits of DMARD therapy are realized. What specific reason did the American College of Rheumatology give for its change of view?